William Blair Weighs in on Upstream Bio Q4 Earnings

Upstream Bio, Inc. (NASDAQ:UPB - Free Report) - Stock analysts at William Blair issued their Q4 2024 earnings per share estimates for shares of Upstream Bio in a research note issued on Tuesday, November 5th. William Blair analyst M. Phipps forecasts that the company will earn ($0.42) per share for the quarter. William Blair has a "Outperform" rating on the stock. William Blair also issued estimates for Upstream Bio's FY2025 earnings at ($2.36) EPS, FY2026 earnings at ($2.64) EPS, FY2027 earnings at ($2.15) EPS and FY2028 earnings at ($2.26) EPS.

A number of other research analysts have also commented on UPB. JPMorgan Chase & Co. initiated coverage on shares of Upstream Bio in a research note on Tuesday. They issued an "overweight" rating and a $38.00 price target on the stock. TD Cowen began coverage on Upstream Bio in a research note on Tuesday. They set a "buy" rating on the stock. Finally, Piper Sandler began coverage on Upstream Bio in a report on Tuesday. They set an "overweight" rating and a $75.00 price target for the company.

Upstream Bio Price Performance

Shares of UPB traded up $0.45 during trading hours on Thursday, hitting $27.02. The company had a trading volume of 119,376 shares, compared to its average volume of 339,030. Upstream Bio has a 12 month low of $20.74 and a 12 month high of $29.46.

Insiders Place Their Bets

In related news, major shareholder Ai Upstream Llc purchased 1,175,000 shares of Upstream Bio stock in a transaction that occurred on Tuesday, October 15th. The shares were acquired at an average price of $17.00 per share, with a total value of $19,975,000.00. Following the completion of the transaction, the insider now directly owns 1,175,000 shares of the company's stock, valued at $19,975,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, Director Erez Chimovits bought 825,000 shares of the firm's stock in a transaction on Tuesday, October 15th. The shares were purchased at an average cost of $17.00 per share, with a total value of $14,025,000.00. Following the acquisition, the director now directly owns 4,554,873 shares in the company, valued at $77,432,841. This represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Ai Upstream Llc purchased 1,175,000 shares of the business's stock in a transaction dated Tuesday, October 15th. The shares were purchased at an average cost of $17.00 per share, with a total value of $19,975,000.00. Following the acquisition, the insider now owns 1,175,000 shares in the company, valued at $19,975,000. The disclosure for this purchase can be found here.

Upstream Bio Company Profile

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.